A strain is a distinct lineage within a microorganism species. It is often identified by a code such as LGG, BB-12, or I-745. Strains within the same species can behave differently in the gut and interact differently with the body. Evidence for one Lactobacillus strain therefore does not prove that another Lactobacillus strain has the same effect.

A review of clinical studies found that several probiotic groups included strains with evidence of benefit for antibiotic-associated diarrhea and described Saccharomyces boulardii I-745 as especially promising. A separate randomized trial in children found fewer cases with Lactobacillus rhamnosus GG. These

The broad evidence supports a preventive effect in some antibiotic users, but the size of that effect depends on the preparation and the underlying risk of diarrhea. In a randomized pilot study, 36 adults taking amoxicillin-clavulanate received placebo or a defined six-strain Lactobacillus-and-Bifidobacterium product. The probiotic delayed the first diarrheal episode by roughly four to five days. It did not clearly reduce the proportion who developed diarrhea, the number of days with diarrhea, or measured quality-of-life outcomes, and daily stool counts showed no clear difference.

A newer trial illustrates why baseline risk matters. Healthy children receiving outpatient antibiotics had diarrhea rates of about 2% whether they ate yogurt containing Bifidobacterium animalis BB-12 or control yogurt. Adverse events were also similar. This pediatric result does not settle

The studies reviewed here do not establish probiotics as a reliable treatment for global IBS symptoms in adults. One randomized trial enrolled 350 generally healthy adults with self-reported bloating or indigestion. After six weeks, a specific multi-species synbiotic improved gastrointestinal quality of life, bloating, gas, abdominal discomfort, and bowel habits compared with placebo. A synbiotic combines probiotics with ingredients intended to support microorganisms.

That result is promising but narrow. Participants were not studied specifically as adults with diagnosed IBS, and the product also contained pomegranate extract. The trial therefore cannot isolate the contribution of its probiotic strains or support other formulations. Reviews

Short trials in otherwise healthy participants are generally reassuring. The small adult antibiotic trial recorded no adverse effects in either group. Across prevention trials that reported safety, researchers found no meaningful difference in overall adverse events and no serious events attributed to probiotics. Reported gastrointestinal complaints included gas, bloating, nausea, abdominal pain, vomiting, and constipation. These studies were not large enough to exclude rare harms.

Safety evidence from healthy participants does not automatically apply to people with serious illness or impaired immunity. Severe or fatal probiotic-associated infections have been reported in premature infants, and invasive infections have been described in medically vulnerable

A strain is a distinct lineage within a microorganism species. It is often identified by a code such as LGG, BB-12, or I-745. Strains within the same species can behave differently in the gut and interact differently with the body. Evidence for one Lactobacillus strain therefore does not prove that another Lactobacillus strain has the same effect.

A review of clinical studies found that several probiotic groups included strains with evidence of benefit for antibiotic-associated diarrhea and described Saccharomyces boulardii I-745 as especially promising. A separate randomized trial in children found fewer cases with Lactobacillus rhamnosus GG. These

The broad evidence supports a preventive effect in some antibiotic users, but the size of that effect depends on the preparation and the underlying risk of diarrhea. In a randomized pilot study, 36 adults taking amoxicillin-clavulanate received placebo or a defined six-strain Lactobacillus-and-Bifidobacterium product. The probiotic delayed the first diarrheal episode by roughly four to five days. It did not clearly reduce the proportion who developed diarrhea, the number of days with diarrhea, or measured quality-of-life outcomes, and daily stool counts showed no clear difference.

A newer trial illustrates why baseline risk matters. Healthy children receiving outpatient antibiotics had diarrhea rates of about 2% whether they ate yogurt containing Bifidobacterium animalis BB-12 or control yogurt. Adverse events were also similar. This pediatric result does not settle

The studies reviewed here do not establish probiotics as a reliable treatment for global IBS symptoms in adults. One randomized trial enrolled 350 generally healthy adults with self-reported bloating or indigestion. After six weeks, a specific multi-species synbiotic improved gastrointestinal quality of life, bloating, gas, abdominal discomfort, and bowel habits compared with placebo. A synbiotic combines probiotics with ingredients intended to support microorganisms.

That result is promising but narrow. Participants were not studied specifically as adults with diagnosed IBS, and the product also contained pomegranate extract. The trial therefore cannot isolate the contribution of its probiotic strains or support other formulations. Reviews

Short trials in otherwise healthy participants are generally reassuring. The small adult antibiotic trial recorded no adverse effects in either group. Across prevention trials that reported safety, researchers found no meaningful difference in overall adverse events and no serious events attributed to probiotics. Reported gastrointestinal complaints included gas, bloating, nausea, abdominal pain, vomiting, and constipation. These studies were not large enough to exclude rare harms.

Safety evidence from healthy participants does not automatically apply to people with serious illness or impaired immunity. Severe or fatal probiotic-associated infections have been reported in premature infants, and invasive infections have been described in medically vulnerable